Figure 1

Low expression of FAM210B is associated with poor prognosis in cancer patients. (a) FAM210B expression levels in ovarian cancer epithelia (CEPI) samples and normal human ovarian surface epithelia (HOSE) (GSE 14407data set). The expression levels are presented as boxplots and were compared using unpaired Student’s t-test. KM analysis of (b) overall survival in the GSE9891 data set, (c) in the GSE19829 data set, and (d) in the GSE27651 data set. (e) Recurrence-free survival in all breast cancer data sets and (f) first progression survival in all lung adenocarcinoma data sets in KM plotter based on FAM210B expression in the primary tumor patients. (g) FAM210B expression in the breast cancer cell line LM2 cultured alone or with HMVEC-L (human lung microvascular endothelial cells) (GSE9187 data set). (h) FAM210B expression in circulating cancer cells (CCC), cancer cells from primary tumors (PCC), and metastatic lung cells (MCC) in a 4T1 mammary epithelial cancer cell orthotopic mouse model (GSE37344 data set). (i) FAM210B expression in cervical cancer patients with negative and positive lymph nodes (GSE26511 data set). The expression levels are presented as boxplots and were compared using unpaired Student’s t-test. (j) Representative image of SKOV3-luc-GFP primary tumor and peritoneal cavity metastasis. (k) mRNA expression and (l) immunohistocytochemistry (IHC) scores of FAM210B in primary tumor and metastatic site